UK ad­vis­es against cov­er­ing No­var­tis' Kym­ri­ah for adults; Ex-Mast chief Bri­an Cul­ley ap­point­ed CEO at Bi­o­Time

→ Right on the heels of en­dors­ing the use of No­var­tis’ CAR-T Kym­ri­ah in chil­dren, the UK drug price watch­dog NICE is turn­ing its thumbs down for ex­tend­ing its wel­come to adults. “How­ev­er, NICE does recog­nise that No­var­tis’ ti­s­agen­le­cleu­cel-T, al­so known as Kym­ri­ah, has sig­nif­i­cant clin­i­cal ben­e­fits, and would wel­come fur­ther dis­cus­sions on its cost-ef­fec­tive­ness.”

→ De­gen­er­a­tive dis­ease spe­cial­ist Bi­o­Time $BTX has tapped Bri­an Cul­ley as its new CEO, tak­ing up a role pre­vi­ous­ly shared by Adi Mo­han­ty and Michael West. Cul­ley helmed Mast Ther­a­peu­tics for sev­en years be­fore a failed lead pro­gram dragged it down and left it with lit­tle op­tion oth­er than serv­ing as a shell for Savara’s re­verse merg­er. West will now move on­to the chief ex­ec­u­tive role at AgeX, a Bi­o­Time af­fil­i­ate fo­cused on age-re­lat­ed de­gen­er­a­tive ail­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER